Background & Aims: Glucagon action in the liver is essential for control of glucose homeostasis and the counterregulatory response to hypoglycemia. Because receptors for the related peptides glucagon-like peptide-1 and glucagon-like peptide-2 regulate ␤-cell and enterocyte apoptosis, respectively, we examined whether glucagon receptor (Gcgr) signaling modulates hepatocyte survival. Methods: The importance of the Gcgr for hepatocyte cell survival was examined using Gcgr؉/؉ and Gcgr؊/؊ mice in vivo, and murine hepatocyte cultures in vitro. Results: Gcgr؊/؊ mice showed enhanced susceptibility to experimental liver injury induced by either Fas Ligord activation or a methionineand choline-deficient diet. Restoration of hepatic Gcgr expression in Gcgr؊/؊ mice attenuated the development of hepatocellular injury. Furthermore, exogenous glucagon administration reduced Jo2-induced apoptosis in wild-type mice and decreased caspase activation in fibroblasts expressing a heterologous Gcgr and in primary murine hepatocyte cultures. The anti-apoptotic actions of glucagon were independent of protein kinase A, phosphatioylinositol-3K, and mitogen-activated protein kinase, and were mimicked by the exchange protein directly activated by the cyclic AMP agonist 8-(4-chlorophenylthio)-2=-O-methyladerosine-3=, 5=-cyclic monophosphate-cAMP. Conclusions: These findings extend the essential actions of the Gcgr beyond the metabolic control of glucose homeostasis to encompass the regulation of hepatocyte survival.
G lucagon is a 29 amino acid proglucagon-derived peptide released from pancreatic ␣-cells that regulates blood glucose via stimulation of hepatic gluconeogenesis and glycogenolysis. 1 Glucagon also inhibits glycogen synthesis and glycolysis and is the primary counter-regulatory hormone to insulin. Loss of the ␣-cell glucagon response to hypoglycemia and dysregulation of glucagon secretion contribute to the pathophysiology of diabetes mellitus. Because inappropriately increased levels of plasma glucagon increase hepatic glucose production leading to hyperglycemia, there is considerable interest in determining whether diminution of glucagon action may be useful for the treatment of type 2 diabetes. 1 The biological importance of the glucagon receptor (Gcgr) has been analyzed via characterization of GcgrϪ/Ϫ mice that show modest fasting hypoglycemia, and improved glucose tolerance. 2 GcgrϪ/Ϫ mice also show reduced adiposity, decreased circulating triglycerides, improved insulin sensitivity, and increased circulating levels of glucagon-like peptide-1 (GLP-1). 2, 3 Moreover, after high-fat feeding, GcgrϪ/Ϫ mice show decreased body weight and food intake, reduced plasma glucose levels, and improved glucose tolerance. 4 The diabetes-resistant phenotype of GcgrϪ/Ϫ mice, taken together with observations that the glucose-lowering actions of amylin, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors are attributable in part to inhibition of inappropriate glucagon secretion, 5 has rekindled interest in attenuation of glucagon action for the treatment of diabetes. Indeed, reduction of liver Gcgr expression using antisense oligonucleotides leads to reduced hepatic glucose production and amelioration of experimental diabetes 6, 7 and small-molecule Gcgr antagonists attenuate glucagon action in human subjects.
Although glucagon, GLP-1, and GLP-2 exert distinct biological actions through separate G-protein-coupled receptors, 8 these peptides also share overlapping mechanisms of action. GLP-1 and GLP-2 regulate glucose homeostasis and nutrient absorption, respectively, and both peptides enhance cell survival via cAMP-dependent pathways. Intriguingly, glucagon also acts as a growth and/or survival factor for cultured hepatocytes in vitro. 9, 10 To determine the importance of Gcgr action for hepatocyte survival, we studied the consequences of enhanced or disrupted Gcgr signaling in murine hepatocytes. We show here that Gcgr signaling is essential for hepatocyte survival via regulation of cAMP-dependent pathways linked to attenuation of caspase activity.
Materials and Methods Materials
Tissue culture reagents were from Invitrogen (Burlington, Ontario, Canada) and chemicals were from SigmaAldrich (St Louis, MO). Human glucagon was purchased from California Peptides (Napa, CA). H-89, LY294002, and U0126 were from Calbiochem (Gibbstown, NJ). Primary tissue culture plates were from BD Biosciences (San Jose, CA). Anti-Fas antibody (Jo2) was from BD Pharmingen (San Jose, CA) and the exchange protein directly activated by cyclic AMP (Epac) agonist 8-pCPT-Me-cAMP was from Biolog Life Sciences Institute (San Diego, CA).
Baby Hamster Kidney Cell Culture
Baby hamster kidney (BHK):rat Gcgr (rGcgr) cells 11 were cultured in 4.5 g/L glucose and Dulbecco's modified Eagle medium, supplemented with 10% fetal bovine serum containing G418 (0.8 mg/mL). When 70%-80% confluence was reached, cells were serum-deprived for 16 -24 hours before induction of apoptosis with cycloheximide.
Cell Viability and Proliferation Assays
Cell viability was assessed by measuring bioreduction of a MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium) tetrazolium salt at 490 nm using the Cell Titer 96 aqueous assay (Promega, San Luis Obispo, CA). Cell proliferation of BHK:rGcgr cells was determined using a bromodeoxyuridine proliferation enzyme-linked immunosorbent assay kit (Roche, Indianapolis, IN).
cAMP Measurement
Measurement of total cAMP was performed using a radioimmunoassay kit from Biomedical Technologies, Inc (Stoughton, MA). Mouse hepatocytes were exposed to 10 mol/L CHX plus 100 ng/mL Jo2 in the absence or presence of glucagon. After 4 -5 hours apoptosis was quantified using the Cell Death enzymelinked immunosorbent assay kit. Data are expressed as fold-increase relative to CHX-alone-treated cultures and are mean Ϯ SD from 2 independent experiments. **P Ͻ .01, ***P Ͻ .001, CHX and Jo2 plus glucagon vs CHX plus Jo2 alone. Cell extracts from primary mouse hepatocytes treated with CHX alone or CHX plus Jo2 with or without glucagon or forskolin for 4 -5 hours were analyzed by Western blotting for (C) cleaved caspase-3 or for (D) DEVD hydrolase activity. Results are representative of 4 independent experiments. DEVDase activity data are mean Ϯ SD and represent 3 independent experiments each performed in duplicate. ***P Ͻ .001, CHX plus Jo2 and glucagon or forskolin vs CHX and Jo2 alone. □, CHX; , Jo2 ϩ CHX; , Jo2 ϩ CHX ϩ GLU; , Jo2 ϩ CHX ϩ FSK.
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Primary Hepatocyte Isolation, Culture, and Adenoviral Infection
Male C57BL/6 or GcgrϪ/Ϫ mice (8 -12 weeks old) were anesthetized with isoflurane/oxygen and hepatocytes were isolated by retrograde, nonrecirculating, in situ collagenase liver perfusion. Cell viability assessed with trypan blue was consistently greater than 90%. Hepatocytes were plated at a density of 40,000 -50,000 cells/cm 2 and were allowed to attach for at least 3 hours before replacement of media with William's E medium lacking serum and insulin and the indicated reagents for 4 -5 hours.
RNA Preparation and Quantitative Real-Time Reverse-Transcription Polymerase Chain Reaction
Total RNA was prepared using Tri-Reagent (SigmaAldrich). First-strand complementary DNA was synthesized using the Superscript II synthesis system (Invitrogen) and random hexamers. Real-time polymerase chain reaction analysis was performed using TaqMan Gene Expression Assays and TaqMan Universal polymerase chain reaction master mix (Applied Biosystems, Foster City, CA) using the ABI prism 7900 Sequence Detection System (AME Bioscience, Toroed, Norway). The primers used were Mm00433546_m1 for the mouse glucagon receptor and Hs99999901_s1 for 18S rRNA (Applied Biosystems).
Adenoviral Transduction
Adenoviruses carrying the rGcgr or LacZ gene were constructed in the laboratory of Chris Rhodes. 12 Transduction of hepatocyte cultures was performed in William's E media without serum or insulin at a multiplicity of infection of 1500 for 12-14 hours. Media then was removed and replaced with serum-free medium containing the indicated reagents for 5-6 hours.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis and Western Blot Analysis
After sodium dodecyl sulfate-polyacrylamide electrophoresis, proteins were electrotransferred onto a Hybond-C nitrocellulose membrane (Amersham, Piscataway, NJ). Blots were incubated with primary antibody overnight at room temperature. Proteins were detected 
Quantification of Apoptosis in Mouse Hepatocyte Cultures
Apoptosis was assessed using the Cell Death Detection enzyme-linked immunosorbent assay PLUS (Roche) through determination of cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes). Alternatively, cells were fixed in 4% paraformaldehyde, nuclei were stained with 20 ng/mL 4=-6-diamidino-2-phenylindole in phosphate-buffered saline (PBS), and scored as apoptotic or healthy according to morphologic criteria. 13 A minimum of 100 nuclei was counted from 4 fields within each treatment. Images were recorded using a Leica DM 1RB microscope, DC 300F camera, and Leica IM5000 software (version 1.2; Leica Microsystems, Bannockburn, IL).
Caspase Activity Assay
Caspase enzymatic activity was assessed by cleavage of fluorogenic substrates (7-amino-4-methylcoumarin) with the specificity of Ile-Glu-Thr-Asp (caspase-8 and -10) or Asp-Glu-Val-Asp (caspase-3 and -7) (Biomol International, Plymouth Meeting, PA). Hepatocytes were lysed at 4°C in 50 mmol/L HEPES, pH 7.4, 75 mmol/L NaCl, 1% Triton X-100, 1 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulfonyl fluoride, 10 g/mL pepstatin A, and 100 KIU/mL aprotinin (Trasylol; Bayer, Pittsburgh, PA), centrifuged at 4°C, and the supernatant was recovered. Enzymatic assays were performed at room temperature, using 50 g of cell lysate and 100 mol/L of fluorogenic substrate in 100 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 0.2% CHAPS, 20 mmol/L dithiothreitol, and 20% glycerol. Caspase-catalyzed release of the fluorophore 7-amino-4-methylcoumarin was monitored by fluorometric analysis (SpectraMax, Gemini; Molecular Devices Corp, Sunnyvale, CA) with an excitation of 380 nm and emission at 460 nm.
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Animal Experiments
All animal experiments were approved by the Toronto General Hospital Animal Care Committee. Male GcgrϪ/Ϫ mice, 8 -12 weeks of age 2 in the C57BL/6 background and littermate controls (Gcgrϩ/ϩ) were assessed for susceptibility to hepatocyte apoptosis using 10 g of Jo2 administered by intraperitoneal injection. Mice were euthanized either after 4 hours or if they showed signs of clinical compromise according to Animal Care
Guidelines. For analysis of glucagon action in vivo, C57BL/6 male mice (8 -9 weeks old) were purchased from Charles River Laboratories (Wilmington, MA), allowed to acclimatize for 1 week, then injected subcutaneously with either 30 ng/g/body weight glucagon in 10% gelatin or gelatin alone. After 30 minutes mice were injected with either 20 g Jo2 or PBS and euthanized after 6 hours. For experiments using specific diets, male mice were fed a diet either deficient in methionine and choline (A02082002B) or a control diet (A02082003B)
Liver Histology
Histopathologic evaluation of liver sections for quantification of apoptosis was performed as described 14 in a blinded manner using the following scoring system: 0, normal (no apoptosis); 1, minimal apoptosis (rare/ occasional apoptotic bodies Ͻ5%); 2, mild apoptosis (up to 25% positivity); 3, moderate apoptosis (up to 75% positivity); and 4, severe apoptosis (75%-100% positivity). For lipid oil red O staining, hepatic steatosis was scored as follows: 0, 0%; 1, 0%-33%; 2, 33%-67%; and 3, 67%-100%. Quantification of cleaved caspase-3 and steatosis in liver sections was performed using the Scanscope slide scanning system and Aperio Positive Pixel Count Algorithm (Aperio Technologies, Inc, Vista, CA).
Statistical Analysis
The statistical significance of differences between Gcgrϩ/ϩ and GcgrϪ/Ϫ mice administered Jo2 was an- alyzed by log-rank or by Mann-Whitney tests. Otherwise, data were analyzed by t test or using analysis of variance where appropriate, with group comparisons performed using Bonferroni multiple comparison post-test.
Results
Mouse hepatocytes showed a dose-dependent increase in levels of cAMP in response to glucagon with a half maximal effective concentration (EC 50 ) of between 0.13 and 0.8 nmol/L (supplementary Figure 1 ; see supplementary material online at www.gastrojournal.org). Activation of the Fas pathway with the Jo2 antibody produced characteristic morphologic signs of apoptosis, including blebbing, chromatin condensation, and cell lysis 13 ( Figure 1A, panel b) ; the morphologic features of apoptosis were markedly attenuated after treatment with 2 nmol/L glucagon or 20 mol/L forskolin ( Figure 1A,  panels c and d, respectively) . Similarly, glucagon significantly reduced (5-to 7-fold) the abundance of cytoplasmic mononucleosomes and oligonucleosomes ( Figure  1B ) and both glucagon and forskolin markedly reduced levels of cleaved caspase-3 ( Figure 1C ) and caspase-3-like DEVD hydrolase activity after Jo2-induced apoptosis (Figure 1D) . Glucagon also reduced hepatocyte apoptosis after The anti-apoptotic actions of Gcgr signaling also were detected in BHK fibroblasts transfected with the rat glucagon receptor (BHK:rGcgr), which showed a dosedependent increase of cAMP accumulation in response to glucagon (supplementary Figure 3A ; see supplementary material online at www.gastrojournal.org). Cycloheximide (CHX) reduced BHK cell viability; however, 20 nmol/L glucagon or 20 mol/L forskolin increased cell viability in CHX-treated cells (Figure 2A) . Furthermore, both glucagon and forskolin reduced levels of cleaved caspase-3, and attenuated reductions in levels of the executioner caspase substrates ␤-catenin and Akt ( Figure  2B ). The preservation of cell viability was not attributable to increased cell proliferation (supplementary Figure 3B ; see supplementary material online at www.gastrojournal. org). Although both glucagon and forskolin stimulate cAMP accumulation and activate protein kinase A (PKA), 1 the PKA inhibitor H-89 did not diminish the cytoprotective actions of glucagon or forskolin in BHK:rGcgr cells ( Figure  2C) . Hence, the Gcgr engages anti-apoptotic signaling pathways in a PKA-independent manner.
We next examined glucagon action in murine hepatocytes. Glucagon stimulated the phosphorylation of CREB and Akt, which was inhibited by the protein kinase inhibitors H-89 and LY294002, consistent with activation of the PKA and PI-3K pathways, respectively. In contrast, glucagon reduced mitogen-activated protein kinase phosphorylation, which was reduced further by the MEK 1/2 inhibitor U0126 ( Figure 3A) . Remarkably, inhibition of PKA, PI-3K, or MEK 1/2 pathways did not interfere with the ability of glucagon or forskolin to attenuate Jo2-induced caspase-3 cleavage ( Figure 3B ) or enhance cell survival (supplementary Figure 4A ; see supplementary material online at www.gastrojournal.org). Furthermore, the ability of glucagon and forskolin to phosphorylate Akt and CREB was preserved in the presence of Jo2 (supplementary Figure 4B ; see supplementary material online at www.gastrojournal.org).
Because glucagon enhances cAMP formation yet exerts cytoprotective effects in a PKA-independent manner, we hypothesized that glucagon regulates apoptosis through activation of Epac, a family of cAMP-regulated guanine nucleotide exchange factors that act independently of PKA. 15 Consistent with this possibility, the Epac agonist CPT-Me-cAMP mimicked the effects of glucagon, leading to reduced caspase-3 cleavage ( Figure 3C ) and significantly (P Ͻ .001) decreased caspase-3-like DEVD hydrolase activity ( Figure 3D ) in mouse hepatocytes after Jo2-induced apoptosis.
Activation of the Fas receptor leads to recruitment of an adaptor molecule Fas-associated protein with death domain that aids in Fas receptor activation and recruits and binds caspase-8, forming the death-inducing signaling complex (DISC). 16 Because cAMP may inhibit DISC formation 17 we assessed whether glucagon interferes with the ability of the DISC to promote caspase-8 activation. Caspase-8 activity was increased in hepatocytes treated with Jo2 and CHX, however, co-incubation with glucagon, forskolin, or CPTMe-cAMP attenuated caspase-8 activation ( Figure 3E ). In contrast, glucagon had no effect on levels of the anti-apoptotic effectors Bcl-xl or Bcl-2 (supplementary Figure 4C ; see supplementary material online at www.gastrojournal.org). Hence glucagon, likely acting via cAMP and Epac, interferes with Fas-induced apoptosis at a proximal level in Fas-DISC signaling.
To determine the importance of endogenous Gcgr signaling for hepatocyte survival we assessed susceptibility to Jo2-induced liver injury in GcgrϪ/Ϫ mice. Jo2 produced more rapid morbidity and increased mortality in GcgrϪ/Ϫ compared with Gcgrϩ/ϩ mice (P Ͻ .05; Figure 4A ). Furthermore, GcgrϪ/Ϫ mice showed a significantly greater median liver apoptotic score ( Figure 4B , P Ͻ .05). A greater proportion of GcgrϪ/Ϫ mice had increased serum levels of transaminases, enzymes released after liver injury, compared with Gcgrϩ/ϩ, with 64% of GcgrϪ/Ϫ vs 33% of Gcgrϩ/ϩ mice showing aspartate aminotransferase (AST) levels greater than 600 U/L. Similarly, 73% of GcgrϪ/Ϫ vs 44% of Gcgrϩ/ϩ mice had alanine aminotransferase (ALT) levels greater than 100 U/L. Immunohistochemical analyses showed more extensive cleaved caspase-3 immunopositivity in GcgrϪ/Ϫ hepatocytes after Jo2 treatment ( Figure 4C and D) . These findings indicate that GcgrϪ/Ϫ mice show enhanced susceptibility to Jo2-induced liver injury.
To address whether the enhanced sensitivity of GcgrϪ/Ϫ mice to liver injury reflects a direct role for the Gcgr in engagement of cell survival pathways, we reintroduced the Gcgr by viral transduction into GcgrϪ/Ϫ hepatocytes. GcgrϪ/Ϫ hepatocytes showed no cAMP accumulation in response to glucagon, but retained responsiveness to forskolin (supplementary Figure 5A ; see supplementary material online at www.gastrojournal.org). Despite increased basal levels of cAMP, 2 GcgrϪ/Ϫ hepatocytes were equally susceptible to Jo2-induced apoptosis (35%-50% of both Gcgrϩ/ϩ and GcgrϪ/Ϫ hepatocytes showed morphologic features of apoptosis) and forskolin, but not glucagon, attenuated features of apoptosis in GcgrϪ/Ϫ hepatocytes ( Figure 5A, panels a-d) . Furthermore, forskolin, but not glucagon, significantly reduced the abundance of cytoplasmic mononucleosomes and oligonucleosomes and decreased levels of cleaved caspase-3 in Jo2-treated GcgrϪ/Ϫ hepatocytes ( Figure 5B and C) . Adenoviral transduction of rGcgr restored glucagonresponsive cAMP production (EC 50 ϭ 0.19 nmol/L) and the anti-apoptotic actions of glucagon in GcgrϪ/Ϫ hepatocytes (supplementary Figure 5B and Figure 5D ).
To ascertain whether partial restoration of hepatic Gcgr expression would mitigate the extent of experimental hepatic injury in vivo, we administered Ad-rGcgr to GcgrϪ/Ϫ mice via intravenous infusion. Hepatic Gcgr expression in GcgrϪ/Ϫ mice (supplementary Figure 6A ; see supplementary material online at www.gastrojournal. org) was associated with a significant reduction in plasma glucagon levels and a significant increase in ambient plasma glucose compared with Ad-LacZ-transduced mice (P Ͻ .001, Figure 6A ; and P Ͻ .01, supplementary Figure  6B , respectively). Furthermore, GcgrϪ/Ϫ mice transduced with the Ad-rGcgr showed significantly reduced hepatic injury after Jo2 administration in vivo (P Ͻ .01) ( Figure 6B ). Moreover, a significant reduction in the number of hepatocytes showing immunopositivity for cleaved caspase-3 after Jo2 administration was observed in Ad-rGcgr vs Ad-LacZ-transduced GcgrϪ/Ϫ mice (Figure 6C) . Exogenous glucagon also increased hepatocyte survival after liver injury in wild-type mice. Glucagon administration significantly (P Ͻ .05) lowered the median hepatic apoptosis score ( Figure 6D ) and fewer glucagon-treated mice showed increased levels (Ͼ300 U/L) of serum AST (12.5% vs 50%) and ALT (25% vs 50%) compared with vehicle-treated mice. Furthermore, glucagon markedly reduced the extent of cleaved caspase-3 immunopositivity in liver ( Figure 6E ; P Ͻ .05).
We next examined the susceptibility of GcgrϪ/Ϫ mice to diet-induced liver injury. Gcgrϩ/ϩ and GcgrϪ/Ϫ mice were fed a methionine and choline-deficient diet known to produce experimental liver injury with histopathologic abnormalities characteristic of nonalcoholic steatohepatitis. 18 Control Gcgrϩ/ϩ and GcgrϪ/Ϫ mice received the identical diet supplemented with methionine and choline. Histologic examination of liver tissue showed a significantly greater accumulation of lipid in GcgrϪ/Ϫ mice ( Figure 7A , panel a and b and Figure 7B and C; P Ͻ .05) despite similar levels of food intake, and comparable changes in body weight in both groups of mice (supplementary Figure 7A and B; see supplementary material online at www.gastrojournal.org). Consistent with the greater degree of liver injury ( Figure 7A , panels c-e), plasma glucose was lower in GcgrϪ/Ϫ mice (supplementary Figure 7C ; see supplementary material online at www.gastrojournal.org). Furthermore, histologic features of apoptosis were more evident in GcgrϪ/Ϫ mice after 6 weeks on the methionine and choline-deficient diet (Figure 7A, panel c and d , quantified in Figure 7D ; P Ͻ .05). Taken together, these findings show that loss of Gcgr signaling increases hepatocyte susceptibility to liver injury.
Discussion
Signaling through class B G-protein-coupled receptors 8 is known to promote cell survival. For example, GLP-2 directly reduces apoptosis in cells 19 and in rodents with experimental intestinal injury. 20 Similarly, GLP-1-receptor activation reduced cell death in rodent insulinomas and in rodent and human pancreatic islet ␤-cells. 21 Conversely, Glp1rϪ/Ϫ ␤ cells display enhanced susceptibility to apoptotic injury. 22 Our observations extend these concepts by establishing that endogenous Gcgr signaling plays an essential role in the control of hepatocyte survival.
A potential pathway linking proglucagon-derived peptide receptor activation to control of cell survival is via cAMP 23 because cAMP levels influence cell survival in diverse cell types including hepatocytes. 10, 24, 25 The observation that glucagon, CPT-Me-cAMP, and forskolin enhance cell survival in murine hepatocytes is consistent with accumulating evidence invoking a critical role for cAMP as a key determinant of hepatocyte viability. Although activation of PKA, PI-3K, and Erk1/2 mitogenactivated protein kinase pathways has been linked to enhanced hepatocyte survival, [25] [26] [27] [28] the effects of glucagon to reduce Jo2-induced hepatocyte apoptosis were independent of these signaling pathways. Accordingly, our data are consistent with a role for Epac as a potential downstream mediator of cAMP-dependent, PKA-independent regulation of hepatocyte survival. 24 Several studies have identified a role for cAMP in modulating Fas Ligord (FasL)/CD95 signaling in hepatocytes, resulting in the attenuation of cell death. 10, 17 After FasL binding to CD95, the adaptor molecule Fas-associated protein with death domain is recruited and activates the Fas receptor, leading to subsequent recruitment of caspase-8 to form the DISC. 16 The assembly of the DISC is critical for further downstream apoptotic signaling. Our experiments provide mechanistic understanding of how the Gcgr enhances hepatocyte viability by showing that glucagon and the Epac agonist (CPT-Me-cAMP) inhibit caspase-3 and caspase-8 activity in injured hepatocytes. These findings suggest that attenuation of Fas-induced apoptosis by glucagon and the Epac agonist likely occurs at the level of the formation of the DISC.
Our data showing that GcgrϪ/Ϫ mice show enhanced susceptibility to diet-induced liver injury is consistent with observations linking diet-induced hepatic steatosis with reduced Gcgr expression and decreased sensitivity to glucagon in vivo. Moreover, glucagon directly reduces hepatocyte and fibroblast apoptosis in vitro, strongly implicating the Gcgr as a direct modulator of apoptosis. The demonstration that GcgrϪ/Ϫ mice are more sensitive to the development of steatohepatitis and FasLinduced hepatocyte apoptosis may have implications for strategies directed at interruption of glucagon action for the treatment of type 2 diabetes. 2, 3, 6, 7, 29 The improvement in glucose control mediated by reduced glucagon action theoretically may be accompanied, in vulnerable diabetic subjects, by an increased susceptibility to liver injury. Our studies imply that a threshold level of hepatocyte Gcgr signaling may be optimal for hepatocellular survival. Hence, a more detailed understanding of the relationship between Gcgr signaling and hepatocyte survival under diverse metabolic circumstances seems warranted.
